Skip to content
Home/Contractors/Resilience Government Services, INC.

Federal Contractor Profile

Resilience Government Services, INC.

Federal contracting record: $292M obligated across 18 awards from 2 agencies, FY 2016–2026.

$292M
Total Obligated
18
Award Records
2
Agencies Served
5
NAICS Codes

Company Profile

Parent UEI (Unique Entity Identifier)

GC2RFAZK8G64

CAGE Code

3GQS9

Address

13200 NW NANO CT, ALACHUA, FL, 32516

First Federal Award

Oct 13, 2015

Most Recent Award

Aug 20, 2026

Federal Sales Analytics

Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.

Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).

Top Federal Agencies

Top NAICS Activity

  • 325412

    PHARMACEUTICAL PREPARATION MANUFACTURING

    2 awards

    $165M
  • 541715

    RESEARCH AND DEVELOPMENT IN THE PHYSICAL, ENGINEERING, AND LIFE SCIENCES (EXCEPT NANOTECHNOLOGY AND BIOTECHNOLOGY)

    4 awards

    $102M
  • 541714

    RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY)

    2 awards

    $16M
  • 541711

    RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY

    5 awards

    $8.4M
  • 325414

    BIOLOGICAL PRODUCT (EXCEPT DIAGNOSTIC) MANUFACTURING

    5 awards

    $1.2M

Recent Federal Awards

DateAgencyNAICSDescriptionAmount
Sep 23, 2025Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$1.6M
Sep 10, 2024Department of DefenseW6QK ACC-APG541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$4.5M
Jul 31, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$750K
Jun 25, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541711DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT$314K
May 23, 2024Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$9.0M
Mar 28, 2024Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$3.0M
Mar 26, 2024Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$473K
Feb 21, 2024Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$9.1M
Nov 2, 2023Department of DefenseW6QK ACC-APG541715DS PROCESS CHARACTERIZATION$1000K
Nov 1, 2023Department of DefenseW6QK ACC-APG541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$2.2M
Oct 30, 2023Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$2.8M
Sep 25, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$489K
Sep 12, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541714TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018$3.8M
Aug 25, 2023Department of Health and Human ServicesNATIONAL INSTITUTES OF HEALTH NIAID541711DEVELOPMENT OF LNA14 ANALYTICAL METHODS AND UPSTREAM AND DOWNSTREAM PROCESSES FOR MANUFACTURING, AND SCALE-UP MANUFACTURING AND RELEASE TESTING OF THE PURIFIED LNA14 PRODUCT$485K
Aug 17, 2023Department of DefenseW6QK ACC-APG541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$135K
Aug 8, 2023Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$4.8M
Aug 3, 2023Department of DefenseW6QK ACC-APG541715DS PROCESS CHARACTERIZATION$1.1M
Aug 3, 2023Department of DefenseW6QK ACC-APG541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$400K
Jun 29, 2023Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$4.4M
Jun 23, 2023Department of DefenseW6QK ACC-APG541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$681K
Apr 12, 2023Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$9.8M
Mar 9, 2023Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$12M
Mar 8, 2023Department of DefenseW6QK ACC-APG541715DRUG SUBSTANCE (DS) PROCESS VALIDATION, DRUG PRODUCT (DP) PROCESS VALIDATION, CLINICAL DEVELOPMENT PHASE 3, AND STORAGE/STABILITY FOR THE PROGRAM WITH ULTIMATE GOAL OF U.S. F.D.A. LICENSURE OF BONT MAB G03-52-01 DRUG PRODUCT.$4.4M
Mar 7, 2023Department of DefenseW6QK ACC-APG541715DS PROCESS CHARACTERIZATION$2.0M
Feb 17, 2023Department of DefenseW6QK ACC-APG541715CLINICAL DEVELOPMENT PHASE 2 STUDY$5.6M

Top Compensated Officers

From FFATA executive compensation disclosures. Reported when federal contract activity exceeds the statutory threshold.

  • PETER H KHOURY

    Rank 1 · Reported Sep 16, 2022

    $554K
  • JAMES M MATTHEW

    Rank 2 · Reported Sep 16, 2022

    $401K
  • WILLIAM T HENSLER

    Rank 3 · Reported Jul 16, 2018

    $372K
  • ROBERT V HOUSE

    Rank 4 · Reported Sep 16, 2022

    $345K
  • MICHAEL T COOKE

    Rank 5 · Reported Sep 16, 2022

    $345K

Want to win work like Resilience Government Services, INC.?

Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.